Brownell Robert, Kaminski Naftali, Woodruff Prescott G, Bradford Williamson Z, Richeldi Luca, Martinez Fernando J, Collard Harold R
1 Department of Medicine, University of California San Francisco, San Francisco, California.
2 Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
Am J Respir Crit Care Med. 2016 Jun 1;193(11):1213-8. doi: 10.1164/rccm.201601-0169CI.
Precision medicine is defined by the National Institute of Health's Precision Medicine Initiative Working Group as an approach to disease treatment that takes into account individual variability in genes, environment, and lifestyle. There has been increased interest in applying the concept of precision medicine to idiopathic pulmonary fibrosis, in particular to search for genetic and molecular biomarker-based profiles (so called endotypes) that identify mechanistically distinct disease subgroups. The relevance of precision medicine to idiopathic pulmonary fibrosis is yet to be established, but we believe that it holds great promise to provide targeted and highly effective therapies to patients. In this manuscript, we describe the field's nascent efforts in genetic/molecular endotype identification and how environmental and behavioral subgroups may also be relevant to disease management.
美国国立卫生研究院精准医疗计划工作组将精准医疗定义为一种疾病治疗方法,该方法会考虑基因、环境和生活方式方面的个体差异。人们越来越有兴趣将精准医疗的概念应用于特发性肺纤维化,特别是寻找基于基因和分子生物标志物的特征(即所谓的内型),以识别机制上不同的疾病亚组。精准医疗与特发性肺纤维化的相关性尚待确定,但我们相信它极有可能为患者提供有针对性的高效治疗方法。在本手稿中,我们描述了该领域在基因/分子内型识别方面的初步努力,以及环境和行为亚组如何也可能与疾病管理相关。